

Retevmo[®] (selpercatinib) – New formulation approval

- On April 10, 2024, the <u>FDA approved</u> a new oral tablet formulation of Eli Lilly's <u>Retevmo</u> (selpercatinib).
 - Retevmo was previously approved as an oral capsule.
- Retevmo is approved for the treatment of:
 - Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.
 - Adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.
 - Adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
 - Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
- Warnings and precautions for Retevmo include hepatotoxicity; interstitial lung disease/pneumonitis; hypertension; QT interval prolongation; hemorrhagic events; hypersensitivity; tumor lysis syndrome; risk of impaired wound healing; hypothyroidism; and embryo-fetal toxicity.
- The recommended dosage of Retevmo, based on body weight, is:
 - Less than 50 kg: 120 mg taken orally twice daily with or without food
 - 50 kg or greater: 160 mg taken orally twice daily with or without food
 - Treatment with Retevmo should be continued until disease progression or unacceptable toxicity.
- Eli Lilly's launch plans for Retevmo tablets are pending. Retevmo tablets will be available as a 40 mg, 80 mg, 120 mg, and 160 mg strength.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.